<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911078</url>
  </required_header>
  <id_info>
    <org_study_id>CI-12-079-EU-RD</org_study_id>
    <nct_id>NCT01911078</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)</brief_title>
  <official_title>Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to determine the effects of renal sympathetic
      denervation on insulin resistance and muscle sympathetic nerve activity in patients with
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin resistance from baseline to 3 months after renal denervation</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>To determine the effects of renal sympathetic denervation on insulin resistance (determined by the Homeostasis Model Assessment - Insulin Resistance method) at 3 months after renal denervation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle sympathetic nerve activity (MSNA) from baseline to 3 months after renal denervation</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>To determine the effects of renal sympathetic denervation on MSNA at 3 months after renal denervation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance from baseline to 12 months after renal denervation</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>To determine the effects of renal sympathetic denervation on insulin resistance long-term (12 months after renal denervation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle sympathetic nerve activity (MSNA) from baseline to 12 months after renal denervation</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>To determine the effects of renal sympathetic denervation on MSNA long-term (12 months after renal denervation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects receiving renal denervation procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects not receiving renal denervation procedure.
Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal artery ablation with the EnligHTN™ Renal Denervation System.</description>
    <arm_group_label>Renal Denervation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EnligHTN™ Renal Denervation System.</intervention_name>
    <arm_group_label>Renal Denervation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with office blood pressure ≥140/90 mmHg and 24-hour ambulatory blood pressure
             ≥130/80 mmHg at Baseline despite the stable use of at least two anti-hypertensive
             drugs at maximum tolerated doses of the patient for at least 4 weeks

          -  Patient with a fasting glucose ≥100 mg/dL (≥5.6 mmol/L) at Baseline or on drug
             treatment for elevated glucose

          -  Patient with a waist circumference ≥102 cm (≥40 inches) for male or ≥88 cm (≥35
             inches) for female at Baseline

          -  Patient with any of the remaining two metabolic syndrome diagnostic criteria listed as
             follows at Baseline

               -  Triglycerides ≥150 mg/dL (≥1.7 mmol/L) or on drug treatment for elevated
                  triglycerides

               -  High density lipid cholesterol (HDL-C) &lt;40 mg/dL (&lt;1.03 mmol/L) for male or &lt;50
                  mg/dL (&lt;1.30 mmol/L) for female or on drug treatment for reduced HDL-C

          -  Patient is ≥18 and ≤70 years old

          -  Patient must be able and willing to provide written informed consent to participate in
             this clinical investigation

          -  Patient must be able and willing to comply with the required follow-up schedule

        Exclusion Criteria:

          -  Patient with secondary hypertension

          -  Patient with type I diabetes mellitus or type II diabetes mellitus requiring insulin
             therapy

          -  Patient with prior renal angioplasty, renal denervation, indwelling renal stents
             and/or aortic stent grafts

          -  Patient with renal arteries &lt;4.0 mm in diameter

          -  Patient with significant renovascular abnormalities (such as renal artery stenosis
             &gt;30%)

          -  Patient with an estimated glomerular filtration rate (eGFR) of &lt;45 mL/min per 1.73 m2
             using the Modified Diet in Renal Disease (MDRD) formula

          -  Patient with hemodynamically significant valvular heart disease, as determined by
             Study Investigator

          -  Patient has had a myocardial infarction, unstable angina pectoris or cerebrovascular
             accident less than 180 days at Baseline or is expected to have cardiovascular
             intervention within the next 180 days

          -  Patient is in chronic atrial fibrillation/flutter or with severe conduction
             abnormalities or with an implantable cardioverter defibrillator (ICD) or pacemaker
             whose settings cannot allow for radiofrequency (RF) energy delivery

          -  Patient is currently being treated with drugs that cause salt retention (such as
             systemic corticosteroids or fludrocortisone), centrally acting sympatholytic
             antihypertensive drugs, direct vasodilators (such as alpha blockers) and continuous
             positive airway pressure (CPAP) therapy for obstructive sleep apnea

          -  Patient with an active systemic infection or blood-clotting abnormalities or allergy
             to radiographic contrast

          -  Patient is pregnant or of childbearing potential and is not using adequate
             contraceptive methods or nursing

          -  Patient is participating in another clinical investigation

          -  Patient has a life expectancy less than 12 months, as determined by Study Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hippocration Hospital, University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Renal denervation</keyword>
  <keyword>Renal artery</keyword>
  <keyword>Muscle sympathetic nerve activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

